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Objective: Certain anxious/depressed primary care
patients decrease medical utilization after mental health
treatment. Previous research has established demo-
graphic and medical comorbidities as distinguishing these
patients. We asked whether characteristics such as
symptom severity, somatization, or health-related quality
of life (HRQoL) could also distinguish patients who
reduce or increase primary care utilization after mental
health care.
Methods: Primary care patients in a mixed-model HMO
were screened for untreated anxiety with and without
depression, using the Symptom Checklist (SCL-90-R) and
medical records abstractions, and also for HRQoL (SF-
36). We identiﬁed 165 symptomatic patients who subse-
quently received mental health treatment and then deﬁned
two subgroups: 1) offset patients (reduced medical uti-
lization the year after initiation of mental health treat-
ment) (N = 97); and 2) no-offset patients (increased
utilization) (N = 68).
Results: Three HRQoL domains (general health percep-
tions, physical functioning, and role functioning–
physical) predicted increased offset savings in the year
after initiation of mental health treatment. Each point of
improved functioning in these domains was associated
with $4 to $10 of additional offset savings. Somatization-
related comorbidities were predictive of greater addi-
tional costs ($230).
Conclusion: Using models to predict individual patient
costs, we found that HRQoL and somatic comorbidities
did not predict by anxiety/depression symptom severity
or medical comorbidities, but by increasing or decreasing
utilization after mental health care. Patients with higher
functioning levels and no somatic comorbidities were
most likely to reduce utilization. These ﬁndings support
growing evidence for the need of inclusion of reliable indi-
cators of somatization and patients’ functioning in offset
research and inpatient care.
Keywords: depression, anxiety, somatization, health-
related quality of life, medical offset, outcomes of mental
health care.
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ABSTRACT
Introduction
A considerable amount of literature establishes that
anxiety and depression are common in the primary
care patient population; these conditions frequently
remain untreated and are associated with poor
health-related quality of life (HRQoL) and also
with unusually high rates of medical utilization
[1–4]. A closely related body of research, the so-
called “offset” literature, indicates that when clini-
cally anxious or depressed patients are treated for
their mental health conditions, they may reduce
their medical utilization, thus generating savings
that may offset the costs of mental health treatment.
While no deﬁnitive explanation has been estab-
lished for the mechanism of this offset effect, one
common interpretation is that mental health care,
while reducing emotional distress, also reduces
somatic symptoms and the tendency to seek medical
attention repeatedly in the absence of serious or
treatable medical conditions [4,5]. However, recent
ﬁndings highlight how difﬁcult it is to assess
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somatic symptoms; new studies document the vari-
ability in how and to what extent physicians deﬁne
and recognize somatic conditions [6].
Some primary care patients receiving required
mental health treatment respond by reducing
medical utilization, yet others continue to increase
utilization. The estimated proportions of treated
patients achieving an offset in primary medical care
have ranged from 20% to roughly 57% [7–9]. Rel-
atively few studies have attempted to explore what
distinguishes offset patients from others [4]. Simon
et al. [7], for example, suggest that the increased 
utilization observed could be related to the multi-
problem patient, whose treatment of depressed
mood has little impact on his or her larger medical
picture, characterized by chronic medical illness,
poor functional status, and multiple somatic symp-
toms. Thompson et al. [8] found that certain diag-
noses, such as anxiety disorders, heart disease,
cancer, and chronic fatigue, are more common
among patients who experience a cost offset.
Patient demographics have also been associated
with likelihood of offset: Mumford et al. [9] found
that persons greater than 55 years of age are more
likely to have larger offset savings.
In addition to such retrospective study ﬁndings,
a few prospective studies offer evidence that soma-
tization and health-related functioning and well-
being are related to the probability of realizing the
offset. A series of studies by Smith et al. [10,11]
demonstrated a substantial reduction in utilization
when primary care physicians manage somatizing
patients by following a program that discouraged
diagnostic activities, because such an approach
might “reinforce the patient’s belief that the symp-
toms have an elusive physical cause.” This patient
management program also yielded an improvement
in health-related physical functioning status.
Manning and Wells [3] found in the RAND health
insurance experiment, patients’ own reports of their
physical functioning levels, such as reported on the
General Health Perception Index survey and several
other patient surveys, had an independent effect on
outpatient medical utilization. They found that con-
trolling for health-related physical health status
noticeably reduced the correlation between mental
distress and higher utilization [3]. Findings such as
these led us to ask whether anxiety/depression
symptom severity, somatization, and functioning
status—particularly physical functioning—might
also help to explain the differences between those
patients who do and those who do not reduce
medical utilization after the initiation of mental
health care.
Methods
Study Design
This study is based on chart review and involves no
randomization, mandated interventions, or addi-
tional surveys. Screening data from an earlier study
were combined with data collected via in-depth
chart review. Our primary objective was to ﬁnd
diagnostic factors that could distinguish patients
who offset costs who had increased costs.
Data Sources and Subpopulation Studies
We used a database created in an earlier prospec-
tive study that was conducted in 1991 and 1992;
results are reported in several publications [12–17].
In this study, 6307 patients were screened for
untreated anxiety and/or depression at 23 prim-
ary care clinics of a large (enrollment greater than
100,000), mixed-model HMO located in the
Denver, Colorado, area. Data relating to symptoms
of anxiety and depression, as measured by the
Symptom Checklist (SCL-52), and data for
HRQoL, as measured by the Short-Form Health
Survey (SF-36), were collected diagnostically at this
screening.
The current study sample derives from 1954
symptomatic patients from the earlier study whose
full primary care utilization history was available
over the 3-year study period beginning 18 months
before the screening date and ending 18 months
after the screening date. These patients came from
22 of the 23 original sites. On-site chart abstraction
was used to collect information about medical uti-
lization, including mental health treatment, drug
therapy, and diagnoses.
Within the study sample, we further identiﬁed
264 patients who began mental health treatment
during the period of study. In the newly treated
group, we deﬁned a subgroup of 165 patients whose
mental health treatment included a therapeutic dose
of a psychotropic medication. We also identiﬁed 
an additional 1121 patients who demonstrated 
clinically signiﬁcant levels of anxiety, depression, or
both, based on diagnostic screening tests, but were
untreated for any mental health condition during
the 6 months before the screening and during the
follow-up period. A study schemata of the study
group selection process is described in Figure 1.
Deﬁning the core study sample was a crucial
element of the study design. We focused our inves-
tigation on the 165 patients whose mental health
treatment included therapeutic doses of psy-
chotropic medications to ensure that we were
applying a stricter deﬁnition of mental health treat-
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ment. In particular, this requirement would increase
the certainty that our interpretation of chart infor-
mation correctly indicates a mental health inter-
vention. The date of the initial prescription for
psychotropic medication provides a reliable marker
for the initiation of mental health care. Finally, the
presence of drug therapy increases the probability
that the intervention was sufﬁciently intensive to be
effective.
To investigate potential differences between
patients who offset mental health costs by reducing
medical utilization and those who do not, we ﬁrst
had to divide patients within the core sample of 165
into two groups: “offset” and “no-offset.” The cal-
culation that allowed us to assign patients to one
group or the other was based on utilization patterns
during the year after mental health treatment was
started. If a patient’s actual costs were lower than
expected, they fell into the offset group, and to
make this determination, actual primary care
medical costs for the year after initiation of mental
health treatment had to be compared to predicted
costs for the same period.
Study Variables
In addition to diagnostic test results collected at
baseline (Fig. 1), key study variables were deﬁned
as part of the abstraction process. A key outcome,
mental health treatment, was indicated by any of
the following: primary care physician counseling,
referral to mental health specialists or clinic, pre-
scription for a therapeutic dose of a psychotropic
medication, hospitalization for mental health treat-
ment, and diagnostic or procedure codes indicative
of a mental health condition and/or treatment.
Accurate estimates of outpatient utilization
provide the basis for calculating costs and ulti-
mately cost offset. Primary care medical records
were abstracted for a 3-year period and included the
following categories of utilization: physician ofﬁce
visits, nurse ofﬁce visits, extended telephone con-
sultations (with MD or nurse), visits with other out-
patient providers, and diagnostic and laboratory
tests. Prescription drug costs and all specialty care,
including specialty mental health care as well as
inpatient utilization, were not included in this
analysis because data were not completed for most
patients; that is, dosage and frequency were not
recorded, which prevented accurate pricing of med-
ications. Charges were assigned in US$ in 1996 for
all outpatient utilization for ofﬁce visits (doctor,
nurse, and physical therapy), extended telephone
calls, and diagnostic tests and procedures. For the
analysis, we chose to use quarterly costs and yearly
totals.
All diagnostic codes listed in the medical record
as reasons for ofﬁce visits were collected, but
comorbidity was derived from only the seven most
common medical conditions reported for study
group patients: cancer, diabetes, high cholesterol,
hypertension, heart disease, stroke, and asthma. In
addition, we noted any evidence of the nine somatic
conditions most frequently cited in published
studies of high primary care utilization in patients
with emotional conditions, including insomnia,
headaches, migraines, back pain, abdominal pain,
vertigo, chest pain, excessive sweating, and exces-
sive itching [19,20]. We used the ICD-9 codes to
determine if a given patient had any of the nine
Untreated anxiety with and without depression patients 
completing SF-36 HRQoL survey (N = 1954)†
Patients newly treated with psychotropics 
(at therapeutic prescription doses)
(N = 165)
Offset patients
Patients having 
reduced* primary care
medical costs in
subsequent year
(N = 97) 
No-offset patients
Patients having same or
increased* primary care
medical costs in
subsequent year
(N = 68) 
Patients newly treated for anxiety/depression 
during observation period (N = 264)
Patients newly treated 
without psychotropics 
(N = 99) 
Patients remaining 
untreated for mental
health conditions 
(N = 1121)
Figure 1 Study group selection.Note that 569 patients did not meet
the study criteria. *Reduced or increased compared to the level pre-
dicted for similar untreated anxiety patients. †Symptoms of anxiety
and depression—The Symptom Checklist 52 (SCL-52) was used to
measure symptom levels.The SCL-52 is a selection of ﬁve subscales
taken in full from the Symptom Checklist 90–Revised (SCL-90-R).
Four subscales measure types of anxiety (general, phobic, somatic,
and obsessive–compulsive) and a single subscale measures depres-
sion. Possible scores for each subscale range from 30 to 81, with 54
representing the symptom level of nonpatients in normative valida-
tion studies [18]. A cut point of 61 on any of the four anxieties or
one depression scale was used for this study. In reporting anxiety
symptom severity, we present the average across the four anxiety
scales, referred to as the Global Anxiety Score. Because summariza-
tion symptoms may be particularly associated with high utilization,
we also report the average scores for this anxiety subscale separately.
Health-related quality of life—Patients also completed the Short-
Form Health Survey (SF-36) (also known as the RAND 36-Item
Health Survey). This survey includes eight domains: physical func-
tioning, social functioning, limitations in daily activity caused by phys-
ical health role (role functioning–physical), emotional problems (role
functioning–emotional),mental health, energy, pain, and general health
perceptions.These subscales are scored from 0 to 100, with 100 rep-
resenting optimal health status. Weighted index scores for physical
and psychological functioning (“standardized component scores”)
were also calculated.
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somatic conditions noted. We did not calculate
scores, but created an indicator variable for pres-
ence of a condition. The ICD-9 code for primary
diagnosis, plus up to four secondary diagnoses,
were reviewed to account for all comorbid condi-
tions. Any prescription for a therapeutic dose of a
psychotropic medication was noted.
Measuring Cost Offset
To perform the comparison of actual primary care
costs to predicted costs for the same period, we ﬁrst
had to calculate predicted costs. Predicted costs
were modeled from the actual costs incurred in the
postscreening year by the group of 1221 similar but
untreated patients who also participated in the
study. This approach uses the untreated patients to
represent the level of expenditure that would be
expected for all patients, assuming that they did not
receive treatment. This method of creating offset
groups required a two-step process. The ﬁrst step
involved using linear regression to develop a pre-
dictive model for post-treatment costs. The second
year’s costs, representing the continuing pattern of
utilization, were regressed on ﬁrst-year quarterly
costs, age, gender, diagnostic scores, which included
total anxiety and depression from screening and
indicators of speciﬁc medical comorbidities (Fig. 2).
The independent variables included in the model are
those factors that are typically used in health eco-
nomics modeling, which are age, gender, and prior
medical costs, and/or those whose effect has been
noted previously in the offset literature, such as
demographics, comorbidity, and severity of symp-
toms. The results of the regression allowed us to
estimate the effect of baseline characteristics of the
untreated group. The predictive model R2 = .12. We
note that a low R2 is often associated with cost
modeling, because distributions of actual dollar
amounts tend to contain extreme values. Log trans-
formation of the cost data improves R2 slightly to
R2 = .14.
Results from the ﬁrst step yielded parameter esti-
mates that were applied in the second step to the
165 newly treated patients. Predicted costs were cal-
culated using the regression results from the ﬁrst
step; independent variables were weighted by the
parameter estimates also from the ﬁrst step (Fig. 2).
The amount of offset was calculated by subtracting
predicted costs from actual costs, which equal the
sum of post-treatment costs from Quarters 5
through 8. Offset costs were used to group patients
into the offset and no-offset groups. Patients with
offset greater than zero, that is, those patients
whose predicted costs exceeded their actual costs,
were classiﬁed in the offset group (N = 97). The
remaining patients (n = 68) were placed in the no-
offset group.
Primary Statistical Analysis
We also note shifts in patterns of expenditure and
utilization over time, because this comparison illus-
trates the offset effect, if any. For treated patients,
“Year 1” comprises the four quarters before the ini-
tiation of mental health treatment, and “Year 2,”
the four quarters after initiation of mental health
treatment. Analyses to compare costs, utilization,
symptom severity, HRQoL, comorbidities, and
somatization between the two offset groups and
patients receiving psychotropic medication were
conducted using Student’s t tests for continuous
measures, chi-square tests for categorical measures,
and multivariate analysis of variance. Also, as a pre-
liminary step, we investigated differences between
patients receiving psychotropic medications and
those newly treated patients who were not treated
with medications for anxiety or depression.
Results
Newly Treated Patients
Psychotropic treatment. Patients whose treatment
regimen included psychotropics at therapeutic
dosing levels differed from patients treated for
mental health conditions without psychotropics
(e.g., counseling by physician or other provider, but
no medications). First, those treated with psy-
chotropics were slightly older (42 vs. 39, P = .03).
Second, their average anxiety symptoms were more
severe (global anxiety score of 66.1 vs. 63.5; p <
.01). Third, they were more likely to report a
comorbid physical condition (88% vs. 73%; p <
.01), and they reported observable, although not
signiﬁcantly, more severe symptoms of somatization
(66.5 vs. 64.6; p = .06). These results can be found
in Table 1.
Comparing Offset and No-Offset Patients
Outpatient expenditure and utilization. When we
compared costs for outpatient care between the two
study groups, we found that the offset group, on
average, reduced predicted expenditure by 50%
(from $507 to $244) the year after initiation of
treatment in Year 2. By comparison, the no-offset
group increased spending by 130% (from $530 to
$1322) of predicted costs for Year 2. The untreated
patients had expenditure patterns similar to the
offset group and below the no-offset group in the
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Variables Units 
Step 1: untreated,
N = 1121, 
mean (SD)
Parameter 
estimates from
Step 1 
P value of
parameter 
estimates 
Dependent variable
Actual outpatient
costs, Y2
Dollars 445.41 (754.02)
Intercept –23.73 .98 
Independent variables 
Age Years 40.22 (10.92) 10.10 .90 
Age2 Years, squared 1,737 (938.55) -0.24 .90 
Age3 Years, cubed 80,023 (64,500) 0.003 .82 
Male 1/0 dummy 0.45 (0.50) –104.30 .022 
Depression at
screening, SCL-52 
Score 30–81, 
symptomatic = 61+ 
63.54 (7.71) –2.11 .54 
Anxiety at
screening, SCL-52 
Score 30–81, 
symptomatic = 61+ 
61.50 (5.46) 4.63 .35 
Q1 costs Dollars 116.28 (602.12) 0.04 .28 
Q2 costs Dollars 99.23 (264.19) 0.30 <.001 
Q3 costs Dollars 108.04 (303.13) 0.09 .23 
Q4 costs Dollars 137.32 (502.46) 0.15 .002 
Cancer 1/0 dummy 0.08 (0.27) 191.30 .020 
Diabetes 1/0 dummy 0.03 (0.16) 208.94 .13 
Hypertension 1/0 dummy 0.13 (0.33) 224.31 .002 
High cholesterol 1/0 dummy 0.08 (0.27) –80.54 .34 
Ischemic heart 1/0 dummy 0.03 (0.16) 383.29 .014 
Stroke 1/0 dummy <0.01 (0.05) –133.08 .76 
Asthma 1/0 dummy 0.04 (0.21) 226.52 .034 
Step 2 (N = 165):
Predicted costs = –23.73 + (AGE * 10.10) + (AGE2 * –0.24) + (AGE3 * 0.003) + 
(MALE 1/0) * –104.30) + (DEPRESSION SCORE * –2.11) + (ANXIETY SCORE * 4.63) + 
(Q1 * 0.04) + (Q2 * 0.30) + (Q3 * 0.09) + (Q4 * 0.15) + (CANCER 1/0 * 191.30) + 
(DIABETES 1/0 * 208.94) + (HYPERTENSION 1/0 * 224.31) + 
(HIGH CHOLESTEROL 1/0 * –80.54) + (HEART DISEASE 1/0 * 383.29) + 
(STROKE 1/0 * –133.08) + (ASTHMA 1/0 * 226.52) 
Figure 2 Results of linear regression model used to develop predicted costs: Step 1, variables, data, and results; Step 2, calculation of pre-
dicted costs.
year before initiation of treatment of Year 1 (Fig.
3). In Year 2, the untreated patients’ utilization
costs remained roughly constant or greater than
that of offset patients but still substantially below
nonoffset patients.
The categories of outpatient utilization for the
two groups are reported in Table 2. In Year 1, the
two groups had similar utilization patterns and
rates in the categories of doctor ofﬁce visits, nurse
ofﬁce visits, and extended telephone consultations,
with the exception of diagnostic and laboratory
testing. In diagnostics and laboratory utilization,
the no-offset group had higher mean rates of usage
than the offset group (4.6 vs. 3.0 such tests in the
year preceding treatment; p = .01).
In Year 2, the offset patient group maintained or
moderately decreased utilization in most categories.
The only category in which the offset patients
markedly increased utilization was the least costly,
extended telephone consultations. The no-offset
patients increased rates of usage in all categories.
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Table 1 Newly treated anxiety patients: those whose treatment included psychotropics compared to those whose treatment
did not include psychotropics
Treatment included Treatment did not 
psychotropics (N = 165) include psychotropics (N = 99) P value
Average age, years (SD) 41.56 (± 9.39) 38.92 (± 9.94) .03
% Female 65 66 .97*
Comorbid physical conditions†
% Reporting one or more conditions 88 73 <.01*
Average No. reported (SD) 1.93 (±1.41) 1.61 (±1.38) .07
Severity of symptoms (as measured by SCL-52 
symptom subscale score)
Global anxiety score‡ (SD) 66.1 (± 6.78) 63.5 (± 6.10) <.01
Summarization score only (SD) 66.5 (± 8.30) 64.6 (± 7.77) .06
Depression score only (SD) 68.0 (± 8.04) 66.8 (± 8.42) .29
*Based on chi-square test.
†From abstractions of patients’ medical records, the following conditions were included in these counts: cancer; diabetes; high cholesterol; hypertension; heart
disease; stroke; asthma; headache; sleep disturbance; miscellaneous digestive disorders; back pain; disequilibrium; chest pain; minor skin conditions; other disorders
of the nervous system; miscellaneous ear, nose, and throat diagnoses; and fatigue.
‡Mean of four anxiety subscales of SCL-52.
Table 2 Medical outpatient utilization categories and rates for offset and no-offset patients—actual
12 months before initiation 12 months after initiation 
of mental health treatment of mental health treatment
Offset patients No-offset patients Offset patients No-offset patients 
Outpatient utilization (N = 97) (N = 68) P value (N = 97) (N = 68) P value
MD ofﬁce visits 3.7 (±3.5) 3.5 (±3.4) .71 3.6 (±2.5) 7.5 (±4.8) <.001
Nurse ofﬁce visits 0.14 (±0.4) 0.47 (±2.4) .18 0.21 (±1.4) 0.68 (±2.7) .14
Extended telephone 
consultation (MD or RN) 0.05 (±0.2) 0.09 (±0.3) .40 0.3 (±0.8) 1.6 (±3.3) <.001
Other specialty provider 
ofﬁce visit 0.37 (±0.8) 0.65 (±2.0) .22 0.40 (±0.7) 0.91 (±1.4) .003
Diagnostic/lab test 3.0 (±3.8) 4.6 (±3.8) .01 2.1 (±1.9) 5.1 (±4.0) <.001
Note: P values for unadjusted comparisons (two-sample Student’s t tests) between offset and no-offset groups, based on time frame. Additionally, some compar-
isons within groups (Year 1 vs.Year 2) were found to be signiﬁcant: no-offset group, MD visits (P < .001) and extended calls (P < .001); offset group, extended calls
(P = .002) and lab tests (P = .03).
$0
$100
$200
$300
$400
1 2 3 4 5 6 7 8
Quarter
Cost per Quarter
No Offset (N=68)
Offset (N=97)
Untreated (N=1121)
No-offset 
Untreated
Offset 
Figure 3 Utilization by patients treated with psychotropic pre-
scriptions: before and after initiation of treatment. Primary care costs
included assigned charges for reported ofﬁce visits (doctor and
nurse), extended telephone consultations with doctors or nurses,
other specialty provider ofﬁce visits, and diagnostic and lab tests.
Mental health care administered by mental health therapists and
pharmacy charges were excluded.
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Their sharpest increases were in physician ofﬁce
visits (3.5–7.5).
Demographics, symptoms, and comorbidities. As
reported in Table 3, offset and no-offset patients
were similar with respect to demographics and
anxiety and depression symptom severity. In partic-
ular, we did not ﬁnd any difference in the two
groups in terms of somatization scores that might
be most closely related to differences in subsequent
utilization levels: both groups reported elevated
mean somatization levels (66.5) and in both groups
a large proportion of patients (76% and 75%)
reported levels above our cut point (≥61). The two
groups were also similar in terms of both standard
and somatization-related comorbidities: they dif-
fered only in a higher incidence of hypertension
among patients in the offset group (24% vs. 9%; 
p = .01).
HRQoL. As presented in Table 4, the unadjusted
values for the two groups were substantially lower
than normative values for a working age popula-
tion. The two groups themselves, however, are
similar in most domains. They differed signiﬁcantly
only if the measure of role functioning–physical,
which captures physical limitations on a patient’s
ability to accomplish daily tasks. That domain was
lower for the no-offset group (42.93 vs. 55.21, p =
.05). Statistical signiﬁcance is no longer achieved,
however, when these values are controlled for age
and sex.
Multivariate analysis of contribution of patient
characteristics, symptom severity, and quality of life
to magnitude of offset. Table 5 presents the multi-
variate regression analysis of the contributions of
patient characteristics and conditions upon the
magnitude of cost occurring in the year after initi-
ation of treatment. In developing the basic model,
we evaluated the contribution of variables singly
and in combination. In addition, we chose to count
comorbidities in categories, grouping somatization-
related comorbid conditions together. Among the
Table 3 Comparing characteristics of patients who did experience medical cost offset and patients who did not experience
medical cost offset
Offset—yes (medical costs Offset—no (medical costs same
decreased) (N = 97) or increased) (N = 68) P value
Average age, years (SD) 40.7 (±8.7) 42.7 (±10.2) .18
% Female 65 66 .87
Comorbid physical conditions
Patients, % (N) 87 90 .55
No. reported 1.82 (±1.18) 2.09 (±1.48) .24
Most common comorbidities (%)
Standard
Hypertension 24 9 .01
Asthma 7 3 .23
Cancer 6 12 .21
High cholesterol 6 9 .52
Diabetes 3 1 .51
Heart disease 1 3 .37
Stroke 1 1 .80
Somatization-related
Back pain 33 29 .63
Headache 32 37 .52
Sleep disturbance 16 18 .85
Fatigue 15 26 .08
Misc. digestive disorders 14 22 .21
Chest pain 9 18 .11
Nervous system 7 9 .71
Disequilibrium 6 10 .34
Minor skin conditions 0 1 .23
Anxiety and depression symptom severity
Anxiety symptoms only
Global anxiety score* 66.7 (±6.9) 65.1 (±6.6) .13
% Reporting elevated (≥61) anxiety symptoms 100 100
Somatization symptoms
Summarization score only 66.5 (±8.4) 66.5 (±8.3) .98
% Reporting elevated (≥61) symptoms 76 75
Depression symptoms
Depression score only 68.6 (±7.8) 67.0 (±8.4) .19
% Reporting elevated (≥61) symptoms 78 82
*Mean of four anxiety subscales of SCL-52.
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basic model variables, only age and somatization-
related comorbidities were signiﬁcantly associated
with changes in outpatient costs. As expected, cost
rose modestly with increasing age. Patients with
somatization-related comorbidities before initiation
of therapy experienced a substantial increase of
$231.63 on average over costs projected for the
year after initiation. Standard comorbidities, on 
the other hand, evidenced an offset of $108.70,
although this level of decrease in costs was not sta-
tistically signiﬁcant.
HRQoL domains were added singularly to the
base model described above. After controlling for
the above conditions and characteristics, we found
that three quality-of-life domains were positively
predictive of the amount of offset (i.e., savings
against predicted utilization) a patient experienced
in the year after initiation of mental health treat-
ment. Each point on the general health perceptions,
physical functioning, and role functioning–physical
scales was found to contribute an additional $10,
$6, and $4, respectively, to medical cost savings in
the subsequent year. The baseline model (Table 5)
had an R2 of .13; including all of the HRQoL
domains increased the R2 to .22.
Conclusions
Our study group of newly treated anxious/
depressed primary care patients appeared compara-
ble to those examined in other studies of medical
offset. Consistent with other studies, our results
found clear evidence of a substantial burden on
function, particularly physical function, associated
Table 4 Health-related quality-of-life scores for offset patients versus no-offset patients
Offset patients No-offset patients Normal population* (matched
SF-36 scores (N = 97) (N = 68) P value for age) (N = 503)
Physical functioning 76.7 (±22.9) 72.8 (±28.3) 0.33 89.70
Role functioning–physical 55.2 (±37.3) 42.9 (±40.6) 0.05 86.66
Bodily pain 56.6 (±23.2) 54.4 (±26.7) 0.59 77.06
General health 57.3 (±19.9) 56.9 (±20.7) 0.89 75.87
Energy/vitality 38.5 (±19.2) 39.6 (±19.2) 0.72 62.42
Social functioning 50.3 (±23.8) 47.7 (±24.3) 0.50 85.75
Role functioning–emotional 34.4 (±37.5) 42.8 (±40.6) 0.18 82.76
Mental health 48.1 (±20.7) 51.2 (±20.6) 0.35 75.12
Standardized physical 
component scores 48.1 (±9.1) 46.3 (±11.5) 0.29 52.15†
Standardized mental 
component scores 32.1 (±11.2) 35.6 (±12.1) 0.08 49.91†
*Data from [25].
†Data from [26].
Table 5 Predictors of primary care cost (multivariate analyses)
Estimated effect P value (for difference
Predictor Mean (SD) on cost ($) from 0)
Basic model variables (included in all models)
Age in years 41.6 (9.4) 16.62 .02
Female (1/0) 0.65 (0.52) -31.30 .82
Number of comorbid conditions
Standard medical comorbidities 0.44 (0.67) -108.70 .28
Related-related comorbidities 1.49 (1.12) 231.63 <.01
Severity of symptoms (SCL-52) (range 30–81)
Global anxiety 66.1 (6.8) -5.91 .65
Depression 68.0 (8.0) 9.32 .41
Additional variables added singularly to basic model
Quality of life (SF-36) (range 0–100)
Physical functioning 75.1 (25.3) -6.08 .03
Role functioning–physical 50.2 (39.0) -3.64 .05
Bodily pain 55.7 (24.6) -2.29 .40
General health perceptions 57.1 (20.2) -9.71 <.01
Energy/vitality 38.9 (19.1) 0.19 .96
Social functioning 49.2 (23.9) -5.84 .06
Role functioning–emotional 37.8 (38.9) -0.18 .93
Mental health 49.3 (20.6) -5.97 .19
Standardized physical component scores 47.4 (10.1) -11.28 .09
Standardized mental component scores 33.5 (11.6) 2.62 .73
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with anxiety and depression as evidenced by unusu-
ally low SF-36 scores for a working-age population.
Our study group was also consistent with previous
ﬁndings of a high prevalence of somatic anxiety and
somatic comorbidities [6,7].
When we divided this group of newly treated
anxious/depressed patients into those who did and
those who did not subsequently reduce predicted
medical utilization, we were surprised to ﬁnd no 
differences in the two groups. Offset and no-offset
patients were similar in the characteristics of age,
fewer medical comorbidities, presence of selected
comorbidities, and higher functioning status, which
earlier research had found to distinguish offset
patients. Nor were the offset patients distinguished
in terms of the descriptors that we had hypothesized
as helping to explain differing medical utilization
patterns after mental health care, which were
symptom severity, somatization, or functioning
status. The two groups were comparable not only
in anxiety and depression symptom severity, but
also in somatization symptoms. But, while elevated
somatization symptoms were common throughout
our study group, as has been well documented in
other anxious/depressed patient studies [6], there
was no difference in frequency or severity between
the offset and no-offset subgroups. Neither was a
higher somatization symptom score, nor overall
anxiety or depression, predictive of levels of 
utilization.
Our multivariate regression analysis, however,
identiﬁed ﬁve factors associated with quantiﬁed
levels of increase or decrease in medical costs: 
age, somatization-related comorbidities, and three
domains of HRQoL as measured by the SF-36
(physical functioning, general health perceptions,
role functioning–physical). These multivariate ﬁnd-
ings of association with amounts of increased or
decreased costs after mental health treatment
suggest that these factors do have an independent
effect on predicted offset.
Our ﬁndings strongly support the role of somatic
comorbidities in determining which patients are
most likely to continue accelerating utilization
despite initiation of mental health care. These con-
ditions proved to have a stronger correlation (p <
.01) with higher than predicted utilization than did
age (p = .02), the other descriptor associated with
continued increase. While studies of offset normally
include standard medical comorbidities, these som-
atizing comorbidities are seldom included or tested
for their inﬂuence on offset. Our ﬁndings suggest
that somatic conditions are a signiﬁcant predictor
of patients’ continued increased utilization and
should be a standard patient descriptor included in
studies of patients’ responses to mental health care.
These ﬁndings initially would seem to contradict
the hypothesis by Smith et al. [10,11] that mental
health care’s effectiveness in allaying patients’
propensity to seek diagnoses and care for somatiz-
ing conditions may be an explanation of the offset
mechanism. However, our managed care patients
may not have received sufﬁciently intense manage-
ment while those in the Smith et al. experimental
program did. If so, a logical extension of our ﬁnd-
ings is that patients with comorbidities and lower
self-report status for physical functioning, role func-
tioning–physical, social functioning, and general
health perception require more intensive manage-
ment to avoid further increases in medical 
utilization.
We found only mixed support for two leading
hypotheses regarding cost offset: the “multiprob-
lem” patient and the alleviation of somatization
symptoms [4,5,21]. Our ﬁndings suggest that the
phenomenon of cost offset is more complex than
either approach would suggest. Our results regard-
ing physical functioning and somatization-related
comorbidities ﬁt the multiproblem patient approach
in that lower functioning and the prevalence of
somatic comorbidities are associated with lack of
offset at best and cost increase at worst. However,
our ﬁndings that standard comorbidities exhibit a
nonsigniﬁcant but large cost offset are inconsistent
with that hypothesis. Other studies by DiMatteo et
al. [22] have indicated that depression and anxiety
in chronically ill patients are associated with addi-
tional risks of treatment noncompliance. If so, then
one explanation of cost offset among those with
standard comorbidities who are treated for depres-
sion would be that successful treatment of mental
distress leads to improved compliance. Our data
provide no support, however, for this alleviation of
somatization hypothesis. Medical comorbidities
were not associated with offset, but somatic com-
plaints were associated with cost increases. A pos-
sible explanation is that these patients may require
more intense intervention, such as tested in the
experiment by Smith et al. [10,11], to achieve cost
offset than that typically available in primary care.
Our observations are tempered by the limitations
inherent in our study. Although we selected patients
with a deﬁned therapy at an appropriate dose, we
do not have other measures of process of care or
clinical outcome to suggest that treatment was suf-
ﬁcient to produce an offset. The analysis rests on
baseline characteristics to predict downstream cost
outcomes after therapy is initiated. We also have
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limited information on patient history of illness and
prior treatment. It may be that some of our vari-
ables, such as somatization-related comorbidities,
are proxies for greater treatment resistance as a
result of multiple past episodes or past treatment
failures. This would help to explain the ﬁnding that
somatization-related comorbidities are associated
with cost increases. Finally, we did not have access
to utilization and cost information for inpatient or
specialty care. A recent cost offset study reported
that primary care utilization, particularly in
managed care settings, may be more sensitive to
patient characteristics as correlates of cost offset
than specialty or inpatient care because use of 
these services is more at the discretion of the patient
[8].
Our ﬁndings highlight the complex natures of
cost offset, somatization, and functioning status.
Given the complexity, the ﬁnancial implications,
and the policy impact of cost offset, future research
needs to move beyond retrospective database
reviews to prospective studies that can more fully
explore the underlying dimensions of offset. The
prospective design of this study allowed us to cut
through a thorny problem in retrospective offset
research, namely, the lack of an appropriate com-
parison group. By using unrecognized patients with
similar levels of severity, we were able to identify a
comparison other than what has been given histor-
ically. At the same time, we deﬁned offset in a new
way based on the concurrent utilization patterns of
the unrecognized group. We also were in position
to take advantage of comorbidity information from
the medical record in deﬁning standard and soma-
tization-related conditions and to determine that
somatization-related comorbidities may play an
important and distinct role in resisting mental
health offset. Finally, with self-report functioning
and well-being information, we were able to test the
effect of these variables on cost offset.
Our prospective study design allowed us to
pursue new avenues of investigation in cost offset.
Our results varied from what might be expected
based on previous research of high utilization of
medical care [23,24]. Findings in this study suggest
that anxious and depressed primary care patients
who also have high levels of physical functioning
and no somatic comorbidities are more likely to
respond to mental health care with a cost offset.
With a better understanding of the correlates of cost
offset and somatization in hand from this and other
studies, appropriately targeted interventions that
more reliably elicit an offset can be tested in exper-
imental design.
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